Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

BMD Changes With BP-lowering Drugs

Studying the effects of various therapies

Publish date:: October 12, 2015

Thiazide diuretic (THZD) users had a slower decline in bone mineral density (BMD) compared to nonusers, while decline among ACE inhibitor (ACEi) and beta blocker (BB) users were similar to rates in nonusers, according to a study of 2,312 women, including 69 ACEi, 71 BB, and 74 THZD users. Researchers found:

• THZD users had a statistically insignificant slower rate of BMD decline in the femoral neck and spine.

• Annual percentage changes in BMD among ACEi and BB users were similar to rates in nonusers.

• Compared to BB, THZD use was associated with a trend toward less annual BMD loss at the spine and a similar trend at the femoral neck.

• Compared to ACEi, THZD use was associated with less loss at the femoral neck, but not at the spine.

Citation: Solomon DH, Ruppert K, Zhao Z, et al. Bone mineral density changes among women initiating blood pressure lowering drugs: a SWAN cohort study. [Published online ahead of print October 8, 2015]. Osteoporosis International. doi: 10.1007/s00198-015-3332-6.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Must Reads in Osteoporosis

Osteoporosis prevalence in PsA similar to general population,

Oral steroids plus PPIs increase osteoporotic fracture risk in RA patients,

Denosumab favored over alendronate for BMD protection in glucocorticoid-induced osteoporosis,

Treatment sequence with romosozumab influences osteoporosis outcomes,

Vertebral fractures in COVID-19 linked to mortality,